Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumours 1Sarcoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 25Radiotherapy 15Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Gemcitabine 5Biopsy 5palbociclib 4Magnetic Resonance Spectroscopy 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3X-Rays 3Vincristine 3Radiation 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2cixutumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liposarcoma × brigimadlin × Clear all
NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 2/3 Completed
400 enrolled 15 charts
Sarcoma

Liposarcoma

NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡